Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
P Dude...I can not believe that the results of such important study as the Brave study were discussed last week in Boston and we have heard nothing about the results...except from a poster on Stock twits...even if the results were negative
PDude...The National Institutes if Health is unlikely to embargo the results of the Brave study, done at the University of Wisconsin in conjunction with the Veterans Administration, until a presentation can be made at the NIH Alzheimers meeting in March 2024...I presume that, if the results of Brave are noteworthy, they will published by Dr. Carlsson soon after analysis of the study data is completed...This will afford time for the medical world to absorb the results of this very important study before discussion at the meeting.
A positive Brave study would make for a very interesting meeting indeed!
jmcrr...Since the Brave study has already been concluded and the results are now being analyzed, I would surmise that the the announcement of the results will be made sometime before the end of the year.
The treatment group is rather small for statistical significance, so I don't expect that to be the case...but I do expect a positive trend for those patients in the study, who were taking Vascepa as opposed to those in the placebo group.
CBB...Quote "perhaps Denner will use it to entice BP into acquiring Amarin to use this new formulation as an adjunct drug for the treatment of cancer, especially lung cancer, and Alzheimer's disease.''....
Another common cancer, which could be potentially treated by this new Amarin formulation of EPA is Lymphoma...which is presently being treated by new ADC's (Antibody Drug Conjugates) and Car-T therapies (T cells, genetically engineered to fight cancer cells), which are beginning to be used...but are "out of this world " expensively priced.
They are presently being used when Chemo therapy, which has serious inflammatory effects, now being treated with intensive steroids, has failed.
A positive Brave study would not only validate Vascepa as a treatment for Altzheimers...but it would also validate the concept that Vascepa's effectiveness is due to its anti-inflammatory qualities....This would further made the case for its use in other inflammatory diseases such as CVD etc.
Its a substitute for steroids...BUT MUCH SAFER
When you have excess inventory in your warehouse, one often used solution is to conduct a time limited sale...such as THREE BOTTLES FOR THE PRICE OF ONE....This could have the following effects...
1. keep old patients
2. stimulate new ones
3. be cheaper than generics
4. turn write offs into cash
5. bring it to the attention of patients and their Docs that a deal is being offered on Vascepa
Denner has proposed that Amarin might think outside the box...This would be a good example of that
Pdude...Jardiance has had the benefit of a vigorous advertising campaign(plus the advent of off patent sales for weight loss)... in addition to their primary indication for diabetes)...Every time I turn on my TV, it seems that I see an add for Jardiance...Only if Amarin is acquired by a BP, could Vascepa have such an advertising campaign.
A positive Brave study could help with increasing sales of Vascepa...by off label sales for Alzheimers.
Vascepa was on the way to being a blockbuster drug until Judge Du ruined it by invalidating the very high trig patent and paving the way for generics to sell Vascepa for the CVD indication...This had several ill effects...
1. Amarin needed to fire many reps, which they have never been able to rehire and probably will never be...thus keeping Docs and the public relatively ignorant about Vascepa
2. Due to a lack of funds, Amarin could not advertise Vascepa as it had previously intended to do
3. New indications for other inflammatory diseases could not be researched and brought to market
4. New forms of EPA also could not be adequately researched and brought to market
Vascepa will be needed even more in the future than it is now.
Extreme heat can take a heavy toll on the heart, and a new report shows how much more deadly the effects of climate change may become over the next few decades in the United States.? Black adults, seniors and people living in urban areas are particularly vulnerable.
Between 2008 and 2019, the heat index – which accounts for both temperature and humidity – reached at least 90 degrees on an average of 54 days each summer in the US. Those days of extreme heat were associated with nearly 1,700 excess cardiovascular deaths each year, according to a study published Monday in the journal Circulation. Extreme heat can take a heavy toll on the heart, and a new report shows how much more deadly the effects of climate change may become over the next few decades in the United States.? Black adults, seniors and people living in urban areas are particularly vulnerable.
Between 2008 and 2019, the heat index – which accounts for both temperature and humidity – reached at least 90 degrees on an average of 54 days each summer in the US. Those days of extreme heat were associated with nearly 1,700 excess cardiovascular deaths each year, according to a study published Monday in the journal Circulation.
Tal...., Funds, which may or may not hold shares, are allowed to ask relevant questions at meetings...Why are we retailers being required to show that we hold shares before we can ask relevant questions at meetings? The important thing is that the questions are judged by Amarin to be relevant befor selecting them...Management can review the questions for relevance and eliminate the ones that are not.
Another Alzheimers drug bites the dust...
QUOTE..."Merck scraps PhII trials of Alzheimer’s and depression small molecule after liver toxicity observations.
Merck has ended work on two separate Phase II studies of its small molecule for treatment-resistant depression and mild-to-moderate Alzheimer’s disease, the pharma confirmed to Endpoints News.
An unblinded review of data from the two trials “suggested MK-1942 was potentially associated with observations of liver toxicity,” a Merck spokesperson told Endpoints in an email Wednesday morning. “This review was triggered by the identification of abnormalities in liver function tests for several study participants. No related Serious Adverse Events (SAE) were reported.”
In updates to ClinicalTrials.gov, the pharma giant cited “benefit/risk assessment” as the reasoning for scrapping the studies of the oral capsule. The Alzheimer’s withdrawal was disclosed this week, and the depression decision was uploaded to the site in September."
Bring on the Brave study with Vascepa, which has been shown to have a placebo like side effect profile...and which will finally demonstrate anti-Alzheimers activity...and at a reasonable cost to patients, who must use it over the long term.
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial results on Wednesday, November 1st, 2023 at 8:00 a.m. ET.
To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow retail and institutional shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call.
Starting on October 19th at 8:00 am ET, all shareholders can submit questions by visiting: https://app.saytechnologies.com/amarin-2023-q3. This Q&A platform will remain open until 24 hours before the start of the earnings call. Shareholders can email support@saytechnologies.com for any support inquiries.
The conference call with management will follow the release of the Company’s third quarter 2023 financial results in the pre-market hours.
Conference Call and Webcast Information:
Access to the live call:
Go to the investor relations section of the Company's website at www.amarincorp.com
Dial in within the United States: 877-545-0523
International dial in: 973-528-0016
Access Code: 991868
Access to replay:
Dial in within the United States: 877-481-4010
International dial in: 919-882-2331
Access Code: 49172
Et-EPA looks interesting...
QUOTE..."Amarin's patent filing for EPAMAX on 8/3/2023 was 232 pages long..IMO Amarin would not have spent all this time and money if they didn't think they had a reasonable reasonable chance of success in getting the patent approved and then developing the product....They probably also assumed that a patient this important and potentially profitable would eventually be challenged by other pharmas and would withstand the challenges. (hopefully better than the Marine patent)"
post #414421 byTal Shu excellently describes this product.
Further information by Amarin on this new product by Amarin in the C.C. would be appreciated .
Jas We should find out more about what the developments in China mean for Amarin in a couple of weeks...
"DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference.
2023 Cantor Global Healthcare Conference (Sept 26 – 28th, 2023; NYC)
Date/Time: Tuesday, Sep 26 at 9:55-10:25 AM ET"
Why Amarin has not issued a timely PR on this subject is a mystery to all of us....this include W.S., which is apparently taking it as bad news??
Tal...I agree...Amarin is a nutritious repast for a BP...The FDC is just the appetizer.
Amarin has never had the nerve to assert in their adds that pure EPA(e.g. Vascepa) has been proven EFFECTIVE in reducing CVD by 20%...while combinations of EPA plus DHA(e.g.Lovaza) have been proven INEFFECTIVE!...Perhaps a BP could have more nerve.
In the article by Dr Ridker, this statement stood out to me..."Inflammation plays a critical role in atherosclerotic cardiovascular disease (ASCVD), a condition where the arteries become narrowed and hardened due to the buildup of plaque, which can lead to heart attacks and strokes. An analysis of three studies recently published in The Lancet found that among patients receiving statins, inflammation was a stronger predictor for risk of future cardiovascular events and death than cholesterol assessed by low-density lipoprotein cholesterol."
So why isn't anti-inflammatory, safe Vascepa used more commonly?
Sleven...Quote..."Overdose warning: Taking too much colchicine can be serious enough to cause death. Never take more of this drug than your doctor prescribes.
Blood disorders warning: Colchicine may cause your body to produce fewer blood cells of different types. This could raise your risk of infection or bleeding because some of these blood cells fight infection and help form blood clots. If you have any blood disorders, talk with your doctor about whether this drug is safe for you.
Muscle damage warning: Colchicine can damage your muscles if you take it for 6 months or longer. Your risk is higher if you’re a senior. Taking other drugs that cause muscle damage, such as cholesterol medications, may increase this risk. colchicine if you’re also taking cholesterol drugs."
Approximately 30 years ago I was put on Cochicine for arthritis...I was having indigestion and stopped it and have not taken it since.
Tal...Thank you for this very interesting article, in which you summarize a 232 page article from the PCT( Patent Cooperation Treaty), dealing with an EPA patent application on an enhanced lymph releasing composition of EPA from Amarin.... I am really interested in this article, especially in the part that deals with the significantly enhanced delivery of LR-EtEPA to the lymph nodes with the possibility of potential benefit to Lymphoma cancer patients.
Have a fever?...Take an Aspirin...Then have your Doc tell you about the other specific meds you should take....as well as the number of Aspirins you should take.
Have cancer?...Take EPA...Then have your Doc tell you about the other specific meds you should take...as well as the number of EPA capsules you should take.
JR...Some newer cancer therapies are so toxic that they have to be administered to patients only during a stay in a hospital...in order to avoid the concurrent, dangerous inflammatory effects of the drugs...a safe, anti-inflammatory drug like EPA could shorten the need for expensive hospitalizations... Therapies like Car-T can run several hundred thousand dollars by themselves.
Especially in the field of oncology, we we are about to arrive at a place where new scientific developments will be outpacing society's ability to pay for them.
could...Lymphoma is a common cancer...It is being treated with toxic doses of chemotherapy, accompanied by high doses of steroids, to allow to patients to tolerate the inflammation brought on by the toxic chemo Rx...A version of EPA, which favors the entry of EPA into lymphoma cancer cells , could lower the amounts of dangerous steroids, necessary to be used used in combating the chemo inflammation, and make the treatment more tolerable and less risky.
An example of how devastating a diagnosis of AD can be was illustrated by a recent case of fraudulent diagnosis of AD in TOLEDO, Ohio
-- QUOTE..."A former director of an Ohio memory-loss clinic accused by dozens of patients of falsely diagnosing them with Alzheimer’s disease has been sentenced on federal fraud charges, along with her physician husband.
Sherry-Ann Jenkins received nearly six years in prison on Tuesday, while Oliver Jenkins(MD) got a 41-month sentence. The couple was convicted in March on conspiracy, mail fraud, wire fraud and health-care fraud charges after being indicted in May 2020.
The U.S. Justice Department has said Sherry-Ann Jenkins was not trained or licensed to provide any medical care but presented herself as a doctor and billed patients for unneeded treatments....The patients said they spent months undergoing treatment while planning out their final years, thinking they would die soon. Some quit their jobs or took one last special trip. One killed himself; others said they considered suicide."
If Vascepa is shown by the Brave study to provide even a modest amount of help in delaying the onset of AD or ameliorating it,(in addition to its positive effect on CVD and other diseases) the drug would be very well received by the world.
Alzheimers is a terrible disease, which , not infrequently, leads to suicide,....Even a mildly positive study would instill some hope in those, who are afflicted.
Gordon...QUOTE FROM HOLT..."China sales for HTG will start late this year"....That would be as much a game changer as R-IT was. The massive China population which could potentially benefit from EPA, would change EVERYTHING regarding inventory, wholesale and retail prices, distribution....AND the value of Amarin.
Its only a few months away...Lets hope that Holt has gotten it right about his most important announcement at his first conference as Amarin CEO this A.M.
-"plans and partner" in place for an authorized generic at any time
-"launch by the end of the year in CHINA"...IMO, this should hasten the decision to have an authorized generic in the U.S.
Holt seems to know his stuff and spouts less BS than previous CEOs...but I wish he wouldn't let the volume of his voice trail off often at the end of his sentences.
Bob...This is Holt's maiden conference with Amarin...I doubt that he would have scheduled it...if he didn't have something of value to impart to us shareholders.
Tal...thank you for your informative post...QUOTE..." kindly find below Background Notes and four (4) questions from which you might wish to pick."
I would pick question 4 from among all these good questions(especially about the authorized generic)... As JT was wont to say..."Vascepa is not a price play... but a volume play"....Sooner or later, Vascepa will be used worldwide...I would have it be sooner.
Institutions don’t care to be linked to a “fish oil company”
Tats...If you made a bet(without odds) that...during the next the next 12 month period... one of two outcomes would occur...
1. Amarin goes bankrupt during this period
2. Amarin achieves serial positive cash flows during this period
Which bet would you take?....And if you choose the second bet, would you consider the stock presently undervalued?
Pdude...Thanks for the article...My personal observations from myself and my wife have lead me to believe that Vascepa has mood elevation as one of its pleiotopic effects...I would like to see studies on that particular function of Vascepa.
Capt...Medicaid patients get their RX's filled at no charge to them...Medicaid patients usually see generalists rather than specialists...So Amarin has to educate generalists about Vascepa....i.e...about Vascepa's efficacy in reducing CVD, but also about its beneficial anti-inflammatory effects in many other diseases.
KIWI...Thanks for this thought provoking article...QUOTE...."They say abnormal amyloid starts to build up in the spaces between neurons, leading to brain INFLAMMATION, which the neurons do not like. This starts to change their internal chemistry."
I suggest the following sequence occurs in Alzheimers...
1. inflammation in brain
2. changes in the internal chemistry of neurons
3. death of neurons
4. deposition of amyloid in brain
5. more inflammation
If we can find a way to reduce the inflammation in the brain, perhaps we can favorably make changes to this vicious cycle.
i. e. ...INFLAMMATION IN THE BRAIN SETS UP A VICIOUS CYCLE!
A positive result from the Brave study would reinforce the evidence that EPA has anti-inflammatory action on Alzheimers disease...This would prod medical science to investigate other conditions, which also are in need of help from an anti-inflammatory drug.
Lymphoma is presently being treated with very toxic anti-cancer chemicals, which, in addition to their beneficial properties, cause severe inflammatory side effects...The anti-cancer chemicals are given along side huge doses of steroids to reduce their inflammatory side effects, especially over a long duration...However, the steroids are ALSO well to known to have serious side effects...EPA, which is a safe and effective anti-inflammatory drug could be used to to reduce the amount of steroids, which need to be given to these sick patients, while preserving the goals of the anti-cancer chemicals....i.e. the steroids could be tapered off while the safe EPA is continued.
JR..."But look at it this way - he is giving everyone ample opportunity to buy low!"
Those of us, who were buying in the double digits can now no longer afford the opportunity to buy low.
Any price lower than the double digits will be vigorously opposed.
Also a reverse split would be an anathema...Even PWO did not propose that miseable scenario in his disastrous stewardship of Amarin...I would rather see Amarin delisted from the the Nasdaq.
Tats...QUOTE..."Denner tells you himself he's playing both sides of this."...I disagree...Denner is only explaining that he has the right to do this...IF he pleases...This is a far cry from saying that he is currently playing both sides.
You are obviously intelligent...but what reason do you have for being so down on Amarin and anyone affiliated with it? ...Have you lost a lot of money on the long side?...Are you now on the short side?
After billions of dollars have been spent in failed trials, aiming to demonstrate that Amyloid is the cause of AD(rather than an effect)...even a modest success in the Brave study, which uses a safe, relatively inexpensive, anti-inflammatory, pure EPA drug, which is administered orally... would have a stunning effect on the medical world and on W.S.
CBB...Your conclusion about the significance of this additional investment in AMARIN by Dr. Denner parallels mine...With this purchase, Denner has made a statement that that he believes in Amarin and is willing to put his reputation on the line.
Those posters, who are constantly and gratuitously insulting Denner...and submit weird theories, without a grain evidence to back them up, and which attribute evil motives to every action he takes, are definitely NOT allies of Amarin or of its shareholders.
I respect these posters when they give information or reasoned opinions about Amarin...not when they give unfounded abuse.
Dr Denner believes that Amarin is way underpriced...and this is his way of stating it.